-
The market value of the vaccine brother plummeted by 20 billion, and the exclusive market of 100 billion yuan was "precarious"
Time of Update: 2022-11-05
On October 27, the opening stock price of vaccine giant Zhifei Biologics fell rapidly, falling by more than 17% at one point. As of midday, Zhifei Biotech's share price closed at 82. 49 yuan per share
-
AI Pharmaceutical: Ready to fly, waiting for the wind? 24 star companies, 67 pipelines, exclusive broadcast!
Time of Update: 2022-11-04
The industrial upgrading of the global pharmaceutical industry is starting around digitalization, intelligence, automation and other directions, AI-assisted drug research and development as one of the
-
Fighting! Battle of 100 regiments at the CGT CDMO track
Time of Update: 2022-11-04
"CGTCDMO Industry Report: Riding the New Wave of CGT Drugs, Rapidly Rising Potential Market", Haitong International Heyuan Biotech's gene therapy CDMO business achieved revenue of 107 million yuan in the first half of the year, an increase of 47.
-
There are only ten clinical studies in the world, what are the ways out for new anti-cancer drugs targeting Nectin-4?
Time of Update: 2022-11-04
Nature Reviews Urology volume 18,pages93–103(2021) Fig. 3 Anti-tumor mechanism of action of Enfortumab vedotin Source: Nature Drug DiscoveryIn 2019, Enfortumab Vedstar (Padcev) is approved by the FDA for the treatment of locally advanced and metastatic urothelial carcinoma, becoming the first and only ADC approved for nectin-4.
-
Multinational pharmaceutical companies return to the "posture" of CNS Industry observation
Time of Update: 2022-11-04
Compared with the earlier years when the industry rushed to the mechanism of amyloidosis, the multi-dimensional and multi-directional layout, the introduction of new technologies and new targets may be a wiser and risk-reducing choice☆ The field of the central nervous system has returned to the vision of big pharmaceutical companies such as Pfizer and Roche with the help of new technologies such as gene therapy and nucleic acid therapy.
-
In the game of big powers, when will the dual pressure of "biology + Chinese core" be lifted
Time of Update: 2022-11-04
IPO prospectus of Oriental Biologics In fact, biochips are widely used in various industries in society, because of its fast, high-throughput, low-cost, portable many advantages, biochip technology in drug screening, disease diagnosis (such as new coronavirus detection), judicial identification, individualized treatment, environmental monitoring, food safety, agricultural biology, military engineering and other fields play an important role.
-
In the 6th year of marketing, the world's first CAR-T therapy "can't sell"
Time of Update: 2022-11-04
Up to now, there are three CAR-T therapies for patients with diffuse large B-cell lymphoma overseas, namely the above-mentioned Kymriah, Yescarta and Breyanzi.
Up to now, there are three CAR-T therapies for patients with diffuse large B-cell lymphoma overseas, namely the above-mentioned Kymriah, Yescarta and Breyanzi.
-
Express More than 80% protection, Pfizer RSV vaccine reached the phase 3 clinical endpoint in newborns for the first time
Time of Update: 2022-11-04
Data analysis showed that the vaccine has more than 80% of the protection, that is, those pregnant women who are vaccinated, the fetus can effectively avoid RSV-related lower respiratory tract disease (severe MA-LRTI) of the severity of infection and medical care within 90 days of birth.
-
Recently, the news of a large number of drugs and devices being approved is continuing to come
Time of Update: 2022-11-04
Broncus Medical announced on the Hong Kong Stock Exchange that the company's innovative product "Wuquan ™" disposable endoscopic atomization microcatheter in the field of drug-device combination was officially approved for marketing by the Zhejiang Provincial Drug Administration.
-
On the same day, two domestic pharmaceutical companies announced that their API products had received CEP certificates
Time of Update: 2022-11-04
【Pharmaceutical Network Industry News】On the evening of October 31, Yongtai Technology and Sirnaomics 2 domestic pharmaceutical companies reported good news that the company's API products recently obtained the European Pharmacopoeia Adaptability Certification Certificate (referred to as "CEP Certificate") issued by the European Agency for the Quality of Pharmaceutical Products.
-
Top 20 R&D expenses of domestic pharmaceutical companies (first three quarters of 2022)
Time of Update: 2022-11-04
As of the evening of October 30, the third quarterly report of A-share listed pharmaceutical companies has basically been disclosed (BeiGene disclosed on November 12); We have compiled the R&D expense
-
Innovent PI3Kδ inhibitor reported to market, Novartis "skuchilumab" new indication approved... Insight Innovative Medicines Weekly
Time of Update: 2022-11-04
AbbVie/Genmab: CD3/CD20 bispecific antibody was declared for marketingOn October 28, AbbVie/Genmab announced that it had submitted an Application for Epcoritamab for Biological Product Licensing (BLA) to the FDA for treatment previously accepted Adult patients with relapsed/refractory large B-cell lymphoma (LBCL) after 2-line or multi-line system therapy.
-
Innovative gene therapies, ADCs... These four innovative drugs are expected to be approved by the FDA in November
Time of Update: 2022-11-04
According to PDUFA's expected target date, it is expected that in November, the US FDA will make a regulatory decision on the approval of 3 innovative drugs. If the approval process is faster, another
-
More than 10 new drugs have been approved in China, from Eli Lilly, Roche, Merck, Hua Medicine, etc. October inventory
Time of Update: 2022-11-04
According to the official website of China's National Medical Products Administration (NMPA) and press releases from various companies, at least 18 new drugs (excluding traditional Chinese medicines a
-
As multinational pharmaceutical companies accelerate their deployment in the Chinese market, they are developing in two directions
Time of Update: 2022-11-04
It is worth mentioning that AstraZeneca CICC Medical Industry Fund has invested in 10 medical and health innovation enterprises more than a year after its establishment.
It is worth mentioning that AstraZeneca CICC Medical Industry Fund has invested in 10 medical and health innovation enterprises more than a year after its establishment.
-
The third quarterly report of A shares ends! Hengrui's major shareholder Tian Xin, WuXi's single-quarter revenue advanced into the "10 billion CLUB", and Zhifei is still riding the dust
Time of Update: 2022-11-04
The curtain has been drawn on the third quarterly report, which companies have a "money-making" effect beyond expectations, and which companies have caught off guard when their performance has changed
-
Battle for the Medicine King! K medicine onslaught, Humeile suffered setbacks, the global top 10 drug ranking in 2022, who is the biggest variable?
Time of Update: 2022-11-04
Johnson & Johnson super "items" are being watched by wolvesAccording to current data forecasts, among the top 10 best-selling drugs in the world this year, the two new crown vaccines of Pfizer's new crown vaccine Comirnaty and Moderna new crown vaccine Spikevax will still be among the best.
-
The first 18A company transformation apocalypse
Time of Update: 2022-11-04
Ascletis remains committed to the fundamentals of viral diseases and is ready to unlock two new markets, including small molecule oral drugs and functional cures of chronic hepatitis B.
-
GSK was placed on the "violation list" and suspended for one and a half years from participating countries
Time of Update: 2022-11-04
Yesterday evening, the Joint Procurement Office of the National Organization for Pharmaceuticals issued an announcement on the cancellation of the eligibility of GlaxoSmithKline (Ireland) Limited (her
-
JAK inhibitor, the successor of the drug king Humirer?
Time of Update: 2022-11-04
But while AbbVie is optimistic, the European Medicines Agency's Safety Committee has issued a recommendation to restrict the use of JAK inhibitors in 4 high-risk groups.
But while AbbVie is optimistic, the European Medicines Agency's Safety Committee has issued a recommendation to restrict the use of JAK inhibitors in 4 high-risk groups.
